Network meta-analysis of effcacy and safety of chemotherapy and target therapy in the first-line setting of advanced pancreatic cancer

Kun I. Lin, Jia Lian Yang, Yu Chao Lin, Che Yi Chou, Jin Hua Chen, Chin Chuan Hung

Research output: Contribution to journalArticle

Abstract

Both gemcitabine and fluoropyrimidine are recommended backbones in the first-line treatment of pancreatic ductal adenocarcinoma (PDAC). To compare the effcacy and safety of these two therapeutic backbones, and to investigate the optimal therapies, we conducted a network meta-analysis. By retrospective analysis of randomized controlled trials (RCT), the most preferred therapeutic regimen may be predicted. The eligible RCTs of the gemcitabine-based therapies and fluoropyrimidine-based therapies were searched up to 31 August 2019. In a frequentist network meta-analysis, treatments were compared and ranked according to overall survival (OS) and progression-free survival (PFS). Thirty-two trials with 10,729 patients were included. The network meta-analyses results for overall survival and progression-free survival showed that fluoropyrimidine-based therapy seems to be the most effective treatment choice. Compared to gemcitabine combined with taxanes or immunotherapy, fluoropyrimidine-based therapy had comparable treatment effects (PFS: 0.67, p-Value = 0.11; 0.76, p-Value = 0.32; OS: 0.80, p-Value = 0.16; 0.77, p-Value = 0.21). Moreover, the combination of immunotherapy and gemcitabine had tolerable toxicities. Based on current evidence, fluoropyrimidine-based therapies and the combination of gemcitabine and taxanes were the most effective therapies in the advanced pancreatic cancer, and the combination of immunotherapy and gemcitabine can be developed into a new form of therapy.

Original languageEnglish
Article number1746
JournalCancers
Volume11
Issue number11
DOIs
Publication statusPublished - Nov 2019

Fingerprint

Pancreatic Neoplasms
gemcitabine
Safety
Drug Therapy
Therapeutics
Immunotherapy
Disease-Free Survival
Taxoids
Network Meta-Analysis
Survival
Adenocarcinoma
Randomized Controlled Trials

Keywords

  • Advanced pancreatic cancer
  • Adverse effects
  • Chemotherapy
  • Effcacy outcomes
  • Target therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Network meta-analysis of effcacy and safety of chemotherapy and target therapy in the first-line setting of advanced pancreatic cancer. / Lin, Kun I.; Yang, Jia Lian; Lin, Yu Chao; Chou, Che Yi; Chen, Jin Hua; Hung, Chin Chuan.

In: Cancers, Vol. 11, No. 11, 1746, 11.2019.

Research output: Contribution to journalArticle

Lin, Kun I. ; Yang, Jia Lian ; Lin, Yu Chao ; Chou, Che Yi ; Chen, Jin Hua ; Hung, Chin Chuan. / Network meta-analysis of effcacy and safety of chemotherapy and target therapy in the first-line setting of advanced pancreatic cancer. In: Cancers. 2019 ; Vol. 11, No. 11.
@article{d7af6019006f4e1eaee92e9c82d260e3,
title = "Network meta-analysis of effcacy and safety of chemotherapy and target therapy in the first-line setting of advanced pancreatic cancer",
abstract = "Both gemcitabine and fluoropyrimidine are recommended backbones in the first-line treatment of pancreatic ductal adenocarcinoma (PDAC). To compare the effcacy and safety of these two therapeutic backbones, and to investigate the optimal therapies, we conducted a network meta-analysis. By retrospective analysis of randomized controlled trials (RCT), the most preferred therapeutic regimen may be predicted. The eligible RCTs of the gemcitabine-based therapies and fluoropyrimidine-based therapies were searched up to 31 August 2019. In a frequentist network meta-analysis, treatments were compared and ranked according to overall survival (OS) and progression-free survival (PFS). Thirty-two trials with 10,729 patients were included. The network meta-analyses results for overall survival and progression-free survival showed that fluoropyrimidine-based therapy seems to be the most effective treatment choice. Compared to gemcitabine combined with taxanes or immunotherapy, fluoropyrimidine-based therapy had comparable treatment effects (PFS: 0.67, p-Value = 0.11; 0.76, p-Value = 0.32; OS: 0.80, p-Value = 0.16; 0.77, p-Value = 0.21). Moreover, the combination of immunotherapy and gemcitabine had tolerable toxicities. Based on current evidence, fluoropyrimidine-based therapies and the combination of gemcitabine and taxanes were the most effective therapies in the advanced pancreatic cancer, and the combination of immunotherapy and gemcitabine can be developed into a new form of therapy.",
keywords = "Advanced pancreatic cancer, Adverse effects, Chemotherapy, Effcacy outcomes, Target therapy",
author = "Lin, {Kun I.} and Yang, {Jia Lian} and Lin, {Yu Chao} and Chou, {Che Yi} and Chen, {Jin Hua} and Hung, {Chin Chuan}",
year = "2019",
month = "11",
doi = "10.3390/cancers11111746",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Network meta-analysis of effcacy and safety of chemotherapy and target therapy in the first-line setting of advanced pancreatic cancer

AU - Lin, Kun I.

AU - Yang, Jia Lian

AU - Lin, Yu Chao

AU - Chou, Che Yi

AU - Chen, Jin Hua

AU - Hung, Chin Chuan

PY - 2019/11

Y1 - 2019/11

N2 - Both gemcitabine and fluoropyrimidine are recommended backbones in the first-line treatment of pancreatic ductal adenocarcinoma (PDAC). To compare the effcacy and safety of these two therapeutic backbones, and to investigate the optimal therapies, we conducted a network meta-analysis. By retrospective analysis of randomized controlled trials (RCT), the most preferred therapeutic regimen may be predicted. The eligible RCTs of the gemcitabine-based therapies and fluoropyrimidine-based therapies were searched up to 31 August 2019. In a frequentist network meta-analysis, treatments were compared and ranked according to overall survival (OS) and progression-free survival (PFS). Thirty-two trials with 10,729 patients were included. The network meta-analyses results for overall survival and progression-free survival showed that fluoropyrimidine-based therapy seems to be the most effective treatment choice. Compared to gemcitabine combined with taxanes or immunotherapy, fluoropyrimidine-based therapy had comparable treatment effects (PFS: 0.67, p-Value = 0.11; 0.76, p-Value = 0.32; OS: 0.80, p-Value = 0.16; 0.77, p-Value = 0.21). Moreover, the combination of immunotherapy and gemcitabine had tolerable toxicities. Based on current evidence, fluoropyrimidine-based therapies and the combination of gemcitabine and taxanes were the most effective therapies in the advanced pancreatic cancer, and the combination of immunotherapy and gemcitabine can be developed into a new form of therapy.

AB - Both gemcitabine and fluoropyrimidine are recommended backbones in the first-line treatment of pancreatic ductal adenocarcinoma (PDAC). To compare the effcacy and safety of these two therapeutic backbones, and to investigate the optimal therapies, we conducted a network meta-analysis. By retrospective analysis of randomized controlled trials (RCT), the most preferred therapeutic regimen may be predicted. The eligible RCTs of the gemcitabine-based therapies and fluoropyrimidine-based therapies were searched up to 31 August 2019. In a frequentist network meta-analysis, treatments were compared and ranked according to overall survival (OS) and progression-free survival (PFS). Thirty-two trials with 10,729 patients were included. The network meta-analyses results for overall survival and progression-free survival showed that fluoropyrimidine-based therapy seems to be the most effective treatment choice. Compared to gemcitabine combined with taxanes or immunotherapy, fluoropyrimidine-based therapy had comparable treatment effects (PFS: 0.67, p-Value = 0.11; 0.76, p-Value = 0.32; OS: 0.80, p-Value = 0.16; 0.77, p-Value = 0.21). Moreover, the combination of immunotherapy and gemcitabine had tolerable toxicities. Based on current evidence, fluoropyrimidine-based therapies and the combination of gemcitabine and taxanes were the most effective therapies in the advanced pancreatic cancer, and the combination of immunotherapy and gemcitabine can be developed into a new form of therapy.

KW - Advanced pancreatic cancer

KW - Adverse effects

KW - Chemotherapy

KW - Effcacy outcomes

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=85074967933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074967933&partnerID=8YFLogxK

U2 - 10.3390/cancers11111746

DO - 10.3390/cancers11111746

M3 - Article

AN - SCOPUS:85074967933

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 11

M1 - 1746

ER -